Jade Clarson

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

D. White, T. Hughes, Amy Hughes, 2017, Blood.

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

J. Reynolds, D. White, T. Hughes, 2019, British journal of haematology.

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

M. Brown, Wenbo Yu, Angel F. Lopez, 2017, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.